Prasugrel Achieves Primary Endpoint in Domestic PIII Trial, Expects to Submit NDA in FY2013: Daiichi Sankyo

Daiichi Sankyo announced September 21 that its antiplatelet agent prasugrel (generic name) achieved the primary endpoint in a PIII clinical trial conducted in Japan with patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). The drug is being...read more